Fasenra

Fasenra (Benralizumab) is a subcutaneous medication used to manage severe eosinophilic asthma. This targeted therapy helps reduce inflammation and improve respiratory function.

Fasenra is primarily used for the treatment of severe eosinophilic asthma in adults and pediatric patients. It works by targeting and depleting eosinophils, a type of white blood cell involved in asthma inflammation. Patients often wonder, 'What is Fasenra used for?' This medication is designed to reduce the frequency of asthma attacks and improve overall asthma control.

Common effects of Fasenra may include reactions at the injection site, such as redness, swelling, or itching. Some patients may also experience headaches or fatigue. These effects are generally mild and temporary, but any persistent or severe reactions should be discussed with a healthcare provider.

Fasenra should be administered under the supervision of a healthcare professional. Patients with a history of hypersensitivity to Benralizumab or any of its components should avoid using this medication. It is important to follow the prescribed dosage and administration guidelines to minimize potential risks.

Fasenra may interact with other medications, including those that affect the immune system. Patients should inform their healthcare provider about all current medications, including over-the-counter drugs and supplements. Alcohol and certain foods may also influence the effectiveness of Fasenra, so it is advisable to discuss lifestyle factors with a healthcare professional.